Table 1 Clinical descriptors of the full cohort and according to the Hoehn & Yahr disease stages two to four.
From: High-Resolution Motor State Detection in Parkinson’s Disease Using Convolutional Neural Networks
parameter | full cohort | HY stage 2 | HY stage 3 | HY stage 4 |
|---|---|---|---|---|
N or mean ± SD (range) | ||||
Gender (male/female) | 20/10 | 9/2 | 9/7 | 2/1 |
Age (years) | 67.1 ± 10.2 (40–83) | 66.1 ± 8.1 (47–73) | 69.5 ± 11.0 (40–83) | 58.0 ± 9.2 (48–66) |
Disease duration (years) | 11.0 ± 5.1 (1–21) | 9.9 ± 6.0 (1–18) | 11.2 ± 4.8 (2–21) | 14.3 ± 2.3 (13–17) |
Levodopa equivalent dose$ | 1109 ± 785 (90–3754) | 1172 ± 1113 (90–3754) | 1053 ± 521 (120–2435) | 1181 ± 806 (675–2110) |
MDS-UPDRS III (ON) | 21.6 ± 15.3 (2–57) | 16.9 ± 15.8 (2–57) | 25.4 ± 15.6 (5–54) | 19.0 ± 7.9 (13–28) |
AIMS (sum items 1–7) | 2.1 ± 2.4 (0–7) | 1.2 ± 1.8 (0–4.5) | 2.5 ± 2.7 (0–7) | 2.9 ± 2.7 (1.25–6.0) |
Montreal Cognitive Assessment | 25.7 ± 2.8 (18–30) | 26.1 ± 1.9 (24–30) | 24.9 ± 3.3 (18–29) | 28.0 ± 1.7 (27–30) |
Body Mass Index (kg/m2) | 25.2 ± 4.8 (12.9–35.4) | 26.9 ± 5.0 (21.6–35.4) | 25.2 ± 3.9 (21.3–35.1) | 19.4 ± 5.8 (12.9–23.7) |
Duration of motion data recording (hours) | 7.5 ± 3.9 (0.4–13.4) | 6.6 ± 4.0 (0.4–12.5) | 8.3 ± 3.8 (2.8–13.4) | 6.5 ± 5.1 (2.6–12.3) |
Additional therapy, i.e. deep brain stimulation (DBS) or continuous subcutaneous apomorphine infusion (CSAI) | DBS = 4 CSAI = 2 | DBS = 1 | DBS = 1 CSAI = 2 | DBS = 2 |
